- Home
- SBRA vs MRUS Comparison
SBRA vs MRUS Comparison
Compare SBRA & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBRA
- MRUS
- Stock Information
- Founded
- SBRA 2010
- MRUS 2003
- Country
- SBRA United States
- MRUS Netherlands
- Employees
- SBRA N/A
- MRUS N/A
- Industry
- SBRA Real Estate Investment Trusts
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- SBRA Real Estate
- MRUS Health Care
- Exchange
- SBRA Nasdaq
- MRUS Nasdaq
- Market Cap
- SBRA 4.3B
- MRUS 5.1B
- IPO Year
- SBRA N/A
- MRUS 2016
- Fundamental
- Price
- SBRA $19.44
- MRUS $96.19
- Analyst Decision
- SBRA Hold
- MRUS Buy
- Analyst Count
- SBRA 9
- MRUS 17
- Target Price
- SBRA $20.56
- MRUS $94.94
- AVG Volume (30 Days)
- SBRA 3.2M
- MRUS 1.3M
- Earning Date
- SBRA 11-05-2025
- MRUS 10-31-2025
- Dividend Yield
- SBRA 6.15%
- MRUS N/A
- EPS Growth
- SBRA 78.50
- MRUS N/A
- EPS
- SBRA 0.73
- MRUS N/A
- Revenue
- SBRA $747,056,000.00
- MRUS $56,606,000.00
- Revenue This Year
- SBRA $7.75
- MRUS $52.81
- Revenue Next Year
- SBRA $9.04
- MRUS N/A
- P/E Ratio
- SBRA $26.78
- MRUS N/A
- Revenue Growth
- SBRA 9.34
- MRUS 57.54
- 52 Week Low
- SBRA $15.60
- MRUS $33.19
- 52 Week High
- SBRA $19.97
- MRUS $96.28
- Technical
- Relative Strength Index (RSI)
- SBRA 66.06
- MRUS 72.69
- Support Level
- SBRA $18.33
- MRUS $95.74
- Resistance Level
- SBRA $18.90
- MRUS $96.18
- Average True Range (ATR)
- SBRA 0.39
- MRUS 0.36
- MACD
- SBRA 0.07
- MRUS -0.39
- Stochastic Oscillator
- SBRA 97.48
- MRUS 89.43
About SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.